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Purpose: This study aimed at exploring the prevalence of self-reported antenatal and postnatal 
depressive symptoms by severity across multiple countries and the association between antide-
pressant treatment in pregnancy and postnatal symptom severity. 
Materials and methods: This was a multinational web-based study conducted across 12 
European countries (n=8069). Uniform data collection was ensured via an electronic question-
naire. Pregnant women at any gestational week and mothers of children with <1 year of age 
could participate. We used the Edinburgh Postnatal Depression Scale (EPDS) to measure the 
prevalence of antenatal and postnatal depressive symptoms according to severity, which were 
corrected by survey weight adjustment (descriptive analysis). Within mothers with a psychiatric 
disorder (n=173), we estimated the association between antidepressant treatment in pregnancy 
and postnatal depressive symptom severity, as standardized EPDS mean scores, via the inverse 
probability of treatment weight (association analysis). 
Results: In the descriptive analysis (n=8069), the period prevalence of moderate-to-very severe 
depressive symptoms was higher in the western and eastern regions relative to the northern 
region, both in the antenatal period (6.8%–7.5% vs 4.3%) and in the postnatal period (7.6% 
vs 4.7%). One in two mothers with psychiatric disorders used an antidepressant in pregnancy 
(86 of 173). In the association analysis, women medicated at any time during pregnancy 
(adjusted β=−0.34, 95% confidence interval [CI] =−0.66, −0.02) had a significant postnatal 
symptom severity reduction compared with the nonmedicated counterpart. This effect was 
larger (β=−0.74, 95% CI =−1.24, −0.24) when the analysis was restricted to mothers within 
6 months after childbirth.
Conclusion: The prevalence of self-reported antenatal and postnatal depressive symptoms 
differs across European countries. Among women with psychiatric disorders, those who had 
been on treatment with antidepressants during pregnancy were less likely to report postnatal 
depressive symptoms, particularly within the 6-month period after childbirth, compared with 
the nonmedicated counterpart.
Keywords: antidepressants, pharmacotherapy, pregnancy and postpartum, depression, anxiety, 
web-based
Introduction
Depression is highly prevalent in the perinatal period and often comorbid with  anxiety.1,2 
During this time, an estimated 1%–6% of women suffer from major depression,3,4 
whereas 15%–25% experience subclinical depression-related symptoms.5 Knowledge 
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about the extent of perinatal depression in low- to middle-
income countries is scarce,6,7 and comparability of prevalence 
estimates across high-income countries remains difficult due 
to dissimilarities in study design, methodology and definition 
of the disorder, the period of prevalence determination, and 
varying cultural correlates.6,8
Postnatal depression is often a continuation or recurrence 
of existing antenatal depression, particularly when the latter 
has been treated suboptimally.9,10 Pharmacotherapy in preg-
nancy constitutes a special challenge for pregnant women 
and clinicians since the effective treatment of the mother 
has to be assured while harmful effects on the unborn child 
must be prevented.11 However, whether antidepressant treat-
ment in pregnancy lowers the risk of relapse of maternal 
depression either during or after pregnancy still remains an 
unanswered question. 
One study12 showed that women discontinuing antide-
pressants in pregnancy had a fivefold increased hazard of 
major depression relapse in the antenatal period relative 
to continuers. While two other studies failed to replicate 
this association,13,14 one study15 reported a protective effect 
of psychotropics on perinatal depression overall, but not 
on depression with postpartum onset. However, these few 
studies mainly assessed the role of medication on antenatal 
and very early postnatal maternal mental health, and none of 
them explored depression in terms of symptom severity and 
from a (multi)dimensional perspective, as advocated by the 
National Institute of Mental Health research domain criteria.16
The aim of this study was twofold: 1) to explore the 
prevalence of antenatal and postnatal depressive symptoms 
across 12 countries in Europe on the basis of the Edinburgh 
Postnatal Depression Scale (EPDS) and 2) to investigate, in 
the postnatal sample, the association between past antide-
pressant treatment in pregnancy and postnatal depressive 
symptom severity among women with a psychiatric disorder.
Materials and methods
Study design and data collection
Data were retrieved from the “Multinational Medication 
Use in Pregnancy Study,” a cross-sectional, web-based study 
carried out in Europe, North and South America, and Aus-
tralia from October 2011 to February 2012, to investigate 
patterns and correlates of medication use in pregnancy.17 
Pregnant women at any gestational age and mothers of 
children under the age of 1 year were eligible for inclusion. 
Data were collected across 18 countries via an anonymous, 
self-administered electronic questionnaire (www.questback.
com), accessible online for a period of 2 months in each par-
ticipating country within the period mentioned above. The 
questionnaire was open to the public through banners posted 
on two to three pregnancy-related websites in each country, 
social networks, and/or pregnancy forums. The websites were 
selected on the basis of the number of daily users. Information 
about the recruitment tools utilized, the Internet penetration 
rates in each participating country, and the full questionnaire 
have been previously published.17
Because the structure of the EPDS responses has been 
shown to differ between Europe and the USA, but not within 
European countries,8 only women with the latter residence 
were included. They were grouped into three regions: 1) 
Western Europe: France, Italy, Switzerland, and the UK; 
2) Northern Europe: Finland, Norway, and Sweden; and 3) 
Eastern Europe: Croatia, Poland, Russia, Serbia, and Slove-
nia. Figure 1 outlines the data selection to achieve the final 
antenatal and postnatal samples. When exploring the period 
prevalence of depressive symptoms (descriptive analysis), 
we analyzed the antenatal and postnatal samples separately. 
When investigating the association between antidepressant 
use in pregnancy and postnatal depressive symptom sever-
ity (association analysis), only the postnatal sample was 
considered. 
Antenatal and postnatal depressive 
symptoms
In the descriptive analysis, the main outcome variables were 
antenatal and postnatal depressive symptom severity as, 
respectively, reported by pregnant women and mothers via 
the EPDS. The EPDS is the most widely used international 
screening questionnaire for the symptoms of depression dur-
ing pregnancy and postpartum.18 It is a self-rating 10-item 
scale validated for major and minor depression in clinical 
settings, with satisfactory Cronbach’s α reliability (0.87).18 
Women were asked to rate whether each item reflected how 
they had been feeling in the past 7 days. Each item response 
scored 0–3 on an ordinal scale, producing a total EPDS score 
of 0–30.18 Higher scores indicated worse symptomatology. 
Due to the lack of a common cutoff value for probable 
depression in all the investigated countries,19,20 we used the 
EPDS as an ordinal variable according to severity level (“no 
symptoms” [score <10], “mild to moderate” [10–16], “mod-
erate to severe” [17–21], and “very severe” [22–30]) in the 
prevalence analysis, as in a previous study.21 The EPDS was 
also explored as a continuous variable to allow comparability 
with prior research.
In the association analysis, the main outcome variable 
was postnatal depressive symptom severity. Because several 
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reports have found the EPDS to be multidimensional rather 
than unidimensional,21–23 we also explored three EPDS subdi-
mensions as in the study by Tuohy and McVey:23 “nonspecific 
depressive symptoms” (items 7–10), “anxiety symptoms” 
(items 3–5), and “anhedonia” (items 1 and 2). We used 
these dimensions since the recruitment strategies in our and 
the abovementioned study23 were comparable. Mean scores 
were calculated and then standardized (z score) for the total 
EPDS and for the three subdimensions when exploring their 
association with past antidepressant treatment. Lower z scores 
indicate lower symptom severity, and higher scores indicate 
the converse. Additional details on the EPDS measure is 
provided in the Supplementary materials.
Psychiatric disorders and antidepressants
Women were confronted with a list of nine chronic disorders, 
including depression and anxiety. A free-text field was also 
available, where any other condition not previously listed 
could be specified. Because depression is highly comorbid 
with anxiety and other psychiatric illnesses,2 we considered 
women reporting depression, anxiety, bipolar, panic, or per-
sonality disorders as having a psychiatric disorder. Women 
were then asked about medication use for each indication as 
free-text entry, along with the timing of usage (pregnancy 
weeks 0–12, 13–24, and 25–delivery). Use of medication and 
timing could also be reported in relation to the treatment of 
various listed short-term illnesses (eg, nausea and sleeping 
problems). Drug classification was based on the Anatomical 
Therapeutic Chemical (ATC) Classification System. Expo-
sure in pregnancy to antidepressants was defined as the use 
of a drug belonging to the ATC group N06A, including 
selective serotonin reuptake inhibitors (SSRIs), serotonin and 
norepinephrine reuptake inhibitors, and tricyclics. As a proxy 
for pharmacotherapy duration, the number of trimesters of 
antidepressant use was defined according to how many time 
intervals were checked in the questionnaires and grouped as 
follows: “none,” “one,” “two, or three” trimesters. Antide-
pressant use in pregnancy constituted the exposure variable 
in the association analysis. 
Covariates
Maternal correlates were categorized as presented in Table 1. 
Pregnancy-related characteristics included time of gestation 
or weeks since childbirth, previous children, perinatal use 
Figure 1 Flow chart to achieve the final antenatal and postnatal samples.
Notes: aPsychiatric disorder refers to self-reported chronic depression, anxiety, bipolar, panic, or personality disorder. Western Europe included France, Italy, Switzerland, 
and the UK; Northern Europe included Finland, Norway, and Sweden; and Eastern Europe included Croatia, Poland, Russia, Serbia, and Slovenia. 
Abbreviation: EPDS, Edinburgh Postnatal Depression Scale.
Women who replied to the
informed consent question,
n=9615
Declined to participate, n=132
n=9483
n=8069
Unknown or ineligible country of residence, n=370
Non-European residence, n=750
European countries with <100 women, n=234
<8 EPDS items completed, n=60
Antenatal sample, n=4308
Northern Europe, n=1579
Eastern Europe, n=1058
Western Europe, n=1671
Postnatal sample, n=3761
Descriptive
analysis
Association
analysis
Self-reported
psychiatric disorder
during pregnancy,a
n=173
Northern Europe, n=1159
Eastern Europe, n=1256
Western Europe, n=1346
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of folic acid, and whether the pregnancy was unplanned. 
Sociodemographic and lifestyle correlates comprised country 
of residency, age, marital status, employment at the time of 
conception, education, mother tongue, smoking habit dur-
ing pregnancy, and alcohol consumption after awareness of 
pregnancy. The personality trait neuroticism was assessed 
via the Big Five Inventory24 and measured by eight items. 
Somatic chronic comorbidity was defined as having asthma, 
allergy, hypothyroidism, epilepsy, diabetes (type I or II), and 
rheumatic or cardiovascular diseases, as self-reported within 
the list of chronic disorders. Women could also indicate 
whether they had experienced nausea or sleeping problems in 
pregnancy, within a list of common acute pregnancy-related 
illnesses. Comedication in pregnancy with acetaminophen, 
anxiolytics and sedatives, antiepileptics, or antipsychotics 
was also measured. 
Table 1 Maternal sociodemographic, lifestyle, and health-related characteristics of the antenatal and postnatal samples, overall and by 
self-reported psychiatric disorder (n=8069)
Antenatal sample Postnatal sample
Total, 
n=4308
Psychiatric disorder Total, 
n=3761
Psychiatric disorder
No, n=4126 Yes, n=182 No, n=3588 Yes, n=173
Pregnancy characteristics
Gestation week (range=1–42), mean (SD) 22.7 (10.2) 22.7 (10.2) 21.6 (10.3)
Weeks since childbirth, n (%)
0–12 784 (20.9) 746 (20.8) 38 (22.0)
13–24 931 (24.8) 904 (25.2) 27 (15.6)
≥25 2046 (54.4) 1938 (54.0) 108 (62.4)
No previous children, n (%) 2413 (56.0) 2311 (56.0) 102 (56.0) 1698 (45.2) 1617 (45.1) 81 (46.8)
No perinatal use of folate,a n (%) 346 (8.0) 332 (8.1) 14 (7.7) 297 (7.9) 285 (7.9) 12 (6.9)
Completely unplanned pregnancy, n (%) 343 (8.0) 325 (7.9) 18 (9.9) 332 (8.8) 301 (8.4) 31 (17.9)
Sociodemographic characteristics
Residence, n (%)
Western Europe 1671 (38.8) 1606 (38.9) 65 (35.7) 1346 (35.8) 1289 (35.9) 57 (32.9)
Northern Europe 1579 (36.7) 1488 (36.1) 91 (50.0) 1159 (30.8) 1077 (30.0) 82 (47.4)
Eastern Europe 1058 (24.6) 1032 (25.0) 26 (14.3) 1256 (33.4) 1222 (34.1) 34 (19.7)
Maternal age (years; range 15–50), mean (SD) 29.5 (5.0) 29.5 (5.0) 29.3 (5.2) 30.0 (5.1) 30.0 (5.0) 30.4 (6.3)
Marital status, n (%)
Married/cohabiting 4110 (95.4) 3949 (95.7) 161 (88.5) 3556 (94.6) 3406 (94.9) 150 (86.7)
Other than above 198 (4.6) 177 (4.3) 21 (11.5) 205 (5.5) 182 (5.1) 23 (13.3)
Working status at conception, n (%)
Employed 3132 (72.7) 3015 (73.1) 117 (64.3) 2836 (75.4) 2746 (76.5) 90 (52.0)
Student 343 (8.0) 328 (8.0) 15 (8.2) 352 (9.4) 321 (9.0) 31 (17.9)
Homemaker 373 (8.7) 357 (8.7) 16 (8.8) 264 (7.0) 237 (6.6) 27 (15.6)
Job seeker/others 454 (10.5) 420 (10.2) 34 (18.7) 305 (8.1) 280 (7.8) 25 (14.5)
Educational attainment, n (%)
Below high school 179 (4.2) 160 (3.9) 19 (10.4) 152 (4.0) 124 (3.5) 28 (16.2)
High school 1741 (40.4) 1659 (40.2) 82 (45.1) 1470 (39.1) 1398 (39.0) 72 (41.6)
Above high school 2388 (55.4) 2307 (55.9) 81 (44.5) 2139 (56.9) 2066 (57.6) 73 (42.2)
Immigrant status (yes),b n (%) 219 (5.1) 209 (5.1) 10 (5.5) 234 (6.2) 227 (6.3) 7 (4.1)
Lifestyle characteristics
Alcohol use during pregnancy (yes),c n (%) 616 (14.3) 579 (14.0) 37 (20.3) 672 (17.9) 639 (17.8) 33 (19.1)
Smoking during pregnancy (yes), n (%) 393 (9.1) 363 (8.8) 30 (16.5) 351 (9.3) 322 (9.0) 29 (16.8)
Neurotic personality traits (range 8–40),d mean (SD) 22.4 (5.6) 22.1 (5.5) 28.4 (5.2) 22.5 (6.1) 22.2 (5.9) 28.5 (5.3)
Health-related characteristics
Medical contact due to fertility problems (yes), n (%) 679 (15.8) 648 (15.7) 31 (17.0) 523 (13.9) 494 (13.8) 29 (16.8)
Nausea in pregnancy (yes), n (%) 3234 (75.1) 3085 (74.8) 149 (81.9) 2626 (69.8) 2492 (69.5) 134 (77.5)
Sleeping problems in pregnancy (yes), n (%) 2572 (59.7) 2435 (59.0) 137 (75.3) 1978 (52.6) 1874 (52.2) 104 (60.1)
Chronic somatic comorbidity (yes),e n (%) 934 (21.7) 827 (20.0) 107 (58.8) 848 (22.6) 741 (20.7) 107 (61.9)
Notes: Missing values were <1.5% for immigrant status, employment, unplanned pregnancy, smoking, fertility problems, folate use, and alcohol use and between 2.5% 
and 3.0% for neuroticism traits. aUse of folate before and/or during pregnancy; bwomen having the first language different from the official main language in the country 
of residence; calcohol consumption after the awareness of the pregnancy; dmeasured via the Big Five Inventory personality scale; edefined as self-reported asthma, allergy, 
hypothyroidism, epilepsy, diabetes (type I or II), and rheumatic or cardiovascular diseases.
Abbreviation: SD, standard deviation.
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Data analysis
Descriptive statistics, corrected by survey weight adjustment, 
were used to characterize the period prevalence of depres-
sive symptom by severity level and mean EPDS scores. The 
survey weight was based on the auxiliary variables age and 
education, which are important correlates of study response. 
Details about the weighting procedure are provided in the 
Supplementary materials. The EPDS internal consistency 
was assessed via reliability analysis.25
To estimate the association between exposure to anti-
depressants during pregnancy and postnatal depressive 
symptom severity as reported by women with a psychiatric 
disorder on the EPDS, we applied inverse probability of treat-
ment weighting (IPTW), using the propensity score to survey 
data, as described by DuGoff et al.26 A logistic regression was 
first fit to estimate the propensity score, ie, the probability of 
“exposure” to antidepressants, 1) at any time during preg-
nancy and 2) in two or three trimesters, given a set of mater-
nal covariates (cf Supplementary materials) and the survey 
weight. We then derived and normalized the IPTW. Balance 
of covariates (standardized difference) between medicated 
and nonmedicated women was assessed after the application 
of the weights and was considered adequate whenever differ-
ences were ≤0.1.27 Lastly, the IPTW was multiplied for the 
sampling weight to generate a new composite weight, which 
was applied to fit generalized linear models.26 Because of 
the small sample size, no IPTW could be computed in rela-
tion to antidepressant use in one trimester only. Because the 
postnatal sample included women with a varying time span 
since delivery, the weighted analyses were stratified accord-
ing to the time since childbirth (<25 and ≥25 weeks). Power 
analysis is outlined in the Supplementary materials.
The crude and adjusted β coefficients with 95% confidence 
interval (CI) represent the standardized mean difference in 
postnatal depressive symptoms between women medicated and 
nonmedicated with antidepressants during pregnancy and can be 
interpreted as the effect sizes of Cohen’s d, where 0.2, 0.5, and 
0.8 are considered a small, medium, and large effect size, respec-
tively.28 Statistical significance was set to p<0.05. All statistical 
analyses were performed by using Stata Version 14 (StataCorp 
LP, College Station, TX, USA). We examined the robustness of 
our findings in a set of sensitivity and exploratory subanalyses, 
as described in detail in the Supplementary materials. 
Ethical approval and informed consent
Informed consent was given by the participants by ticking the 
answer “yes” to the question “Are you willing to participate 
in the study?”. The South-East Regional Ethics Committee 
in Norway granted an ethical approval exemption for the 
original multinational research survey because of anonymity. 
As required by the national legislation, in the UK, the original 
research survey received ethical approval from the University 
of East Anglia’s Faculty of Medicine and Health Research Eth-
ics Committee. In Italy, the Ethic Board of the health district 
of Trento was notified about the original research survey. In 
the remaining European countries, the research survey was 
exempt from ethical approval because of anonymity. All data 
were handled and stored anonymously. The data are available to 
researchers upon the application to the PharmacoEpidemiology 
and Drug Safety Research Group at the University of Oslo. 
Results
This study included 8069 women, whereof 4308 (53.4%) 
were pregnant and 3761 (46.6%) were mothers of children 
younger than 1 year at the time of answering the question-
naire. Figure 1 outlines data selection to achieve the final 
distinct antenatal and postnatal samples for the descriptive 
and association analyses. Overall, 4.4% (n=355; 173 mothers 
and 182 pregnant women) of women reported to have had a 
psychiatric disorder in pregnancy, mainly depression and/or 
anxiety (n=341); of these, 33.4% reported depression, 27.6% 
reported anxiety, and 39.0% reported comorbid depression 
and anxiety. The remaining 14 women had bipolar, panic, 
or personality disorders. Table 1 lists the sociodemographic, 
lifestyle, and health-related characteristics of the antenatal 
and postnatal samples by psychiatric disorder. 
Prevalence of antenatal and postnatal 
depressive symptoms
Figures 2 and 3 present the prevalence of antenatal and post-
natal depressive symptoms by region/country and by severity 
level, whereas Figures S1 and S2 present EPDS mean scores, 
overall and by psychiatric disorder. The period prevalence 
values of moderate to severe and very severe antenatal 
depressive symptoms were in the range of 1.6%–8.4% and 
0.5%–4.5%, respectively (Figure 2); in the postnatal period, 
these were correspondingly 2.6%–11.0% and 0.5%–3.0% 
(Figure 3). In both perinatal periods, the prevalence estimates 
were higher in eastern and western European countries rela-
tive to the northern region. The EPDS had good reliability 
(Supplementary materials).
Association between antidepressant 
treatment during pregnancy and postnatal 
depressive symptom severity
Of the 173 mothers with a psychiatric disorder, 49.7% (n=86) 
reported treatment with an antidepressant any time during 
pregnancy and mainly in two or three trimesters (Table 2). 
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Figure 2 Weighted proportions of women with antenatal depressive symptoms by severity and country of residence.
Notes: Proportions and corresponding 95% CIs were corrected for survey weights based on educational level within age strata for each individual country among women 
of childbearing age. Population data for 2012 from: European Commission, Eurostat. Population by educational attainment level, sex and age (%) - main indicators; 2017 
[updated February 28, 2018; cited November 8, 2017]. Available from: http://ec.europa.eu/eurostat/web/products-datasets/-/edat_lfse_03. Accessed August 17, 2017.49 
Symptoms severity assessed as follows: “mild to moderate” (EPDS score=10–16), “moderate to severe” (EPDS score=17–21), and “very severe” (EPDS score=22–30). The 
proportion of women having no depressive symptoms (EPDS score=0–9) is not represented. In Slovenia, there were no women having moderate to severe or very severe 
depressive symptoms. The squares in red color indicate the proportion of women with mild to moderate depressive symptoms, the ones in green indicate moderate-to-
severe symptoms, and the ones in black indicate very severe depressive symptoms.
Abbreviations: CI, confidence interval; EPDS, Edinburgh Postnatal Depression Scale.
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Figure 3 Weighted proportions of women with postnatal depressive symptoms by severity and country of residence.
Notes: Proportions and corresponding 95% CIs were corrected for survey weights based on educational level within age strata for each individual country among women 
of childbearing age. Population data for 2012 from: European Commission, Eurostat. Population by educational attainment level, sex and age (%) - main indicators; 2017 
[updated February 28, 2018; cited November 8, 2017]. Available from: http://ec.europa.eu/eurostat/web/products-datasets/-/edat_lfse_03. Accessed August 17, 2017.49 
Symptoms severity assessed as follows: “mild to moderate” (EPDS score =10–16), “moderate to severe” (EPDS score =17–21), and ”very severe” (EPDS score =22–30). 
The proportion of women having no depressive symptoms (EPDS score =0–9) is not represented. The squares in red color indicate the proportion of women with mild-to-
moderate depressive symptoms, the ones in green indicate moderate to severe symptoms, and the ones in black indicate very severe depressive symptoms.
Abbreviations: CI, confidence interval; EPDS, Edinburgh Postnatal Depression Scale.
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Table 2 Timing and length of antidepressant use in pregnancy 
among women with a psychiatric disorder in the postnatal sample 
(n=173)
Timing of use Length of use
Anya n (%) Anya n (%)
Any time in pregnancy 86 (49.7) None 87 (50.3)
1st trimester 79 (45.7) 1 trimester 18 (10.4)
2nd trimester 67 (38.7) 2 or 3 trimesters 68 (39.3)
3rd trimester 67 (38.7)
SSRI SSRI
Any time in pregnancy 75 (46.3) None 98 (56.7)
1st trimester 70 (40.5) 1 trimester 15 (8.7)
2nd trimester 59 (34.1) 2 or 3 trimesters 60 (34.7)
3rd trimester 59 (34.1)
SNRI SNRI
Any time in pregnancy 11 (6.4)
1st trimester 10 (5.8) None 162 (93.6)
2nd trimester 8 (4.6) 1 trimester 2 (1.2)
3rd trimester 7 (4.1) 2 or 3 trimesters 9 (5.2)
Notes: aIt includes 1) three women were on combined therapy with an SSRI plus 
a tricyclic antidepressant and 2) one woman was on combined therapy with an 
unspecified antidepressant and an SNRI.
Abbreviations: SNRI, serotonin and norepinephrine reuptake inhibitor; SSRI, 
selective serotonin reuptake inhibitor.
SSRIs were the preferred therapeutic choice and primarily 
as monotherapy. Table 3 outlines maternal correlates and 
comedication use in pregnancy by antidepressant exposure 
for the postnatal sample. 
Table 4 describes the associations between antide-
pressant exposure in pregnancy and postnatal depressive 
symptom severity. In the weighted model, mothers who 
had been medicated at any time during pregnancy (adjusted 
β=−0.34, 95% CI =−0.66, −0.02), or in two or three tri-
mesters, had a significant postnatal symptom severity 
reduction compared with the nonmedicated counterpart. 
The largest effect estimate was observed in relation to 
postnatal anxiety symptom reduction following treatment 
with antidepressants in two or three trimesters (adjusted 
β=−0.44, 95% CI =−0.84, −0.03). In the stratified analy-
sis according to the time since childbirth, treatment with 
antidepressant at any time or in two or three trimesters 
was associated with reduced symptom severity (total 
EPDS) only in the earliest postnatal period (<25 weeks, 
adjusted β=−0.74 [−1.24, −0.24]; ≥25 weeks, adjusted 
β=−0.03 [−0.44, 0.39]). Larger effects were detected on 
the postnatal anxiety and anhedonia EPDS subdimensions 
(Table 4). Descriptive details of the IPTW and results 
of the various sensitivity analyses are described in the 
Supplementary materials. Figures S3 and S4 depict the 
balance between covariates. 
Table 3 Maternal sociodemographic, lifestyle, and health-related 
characteristics of the postnatal sample with psychiatric disorders 
according to antidepressant exposure during pregnancy (n=173)
Antidepressant  
in pregnancy
No, n=87 Yes, n=86
Pregnancy characteristics
Weeks since childbirth, n (%)
0–12 22 (25.3) 16 (18.6)
13–24 14 (16.1) 13 (15.1)
≥25 51 (58.6) 57 (66.3)
No previous children, n (%) 42 (48.3) 39 (45.4)
No perinatal use of folate,a n (%) 5 (5.8) 7 (8.1)
Completely unplanned pregnancy, n (%) 16 (18.4) 15 (17.4)
Sociodemographic characteristics
Residence, n (%)
Western Europe 27 (31.0) 30 (34.9)
Northern Europe 31 (35.6) 51 (59.3)
Eastern Europe 29 (33.3) 5 (5.8)
Maternal age (years; range 15–50),  
mean (SD)
29.0 (6.7) 31.7 (5.5)
Marital status, no (%)
Married/cohabiting 72 (82.8) 78 (90.7)
Other than above 15 (17.2) 8 (9.3)
Working status at conception, n (%)
Employed 42 (48.3) 48 (55.8)
Student 19 (61.3) 12 (38.7)
Homemaker 15 (17.2) 12 (14.0)
Job seeker/others 11 (12.6) 14 (16.3)
Educational attainment, n (%)
Below high school 17 (19.5) 11 (12.8)
High school 39 (44.8) 33 (45.8)
Above high school 31 (42.5) 42 (48.8)
Immigrant status (yes),b n (%) 3 (3.5) 4 (4.7)
Lifestyle characteristics
Alcohol use during pregnancy (yes),c n (%) 19 (21.8) 14 (16.3)
Smoking during pregnancy (yes), n (%) 16 (18.4) 13 (15.1)
Neurotic personality traits (range 8–40),d 
mean (SD) 
28.8 (5.4) 28.2 (5.2)
Health-related characteristics
Medical contact due to fertility problems 
(yes), n (%)
15 (17.2) 14 (16.3)
Nausea in pregnancy (yes), n (%) 66 (75.9) 68 (79.1)
Sleeping problems in pregnancy (yes), n (%) 54 (62.1) 50 (58.1)
Chronic somatic comorbidity (yes),e n (%) 64 (73.6) 43 (50.0)
Comedication in pregnancy
Anxiolytics and sedatives 8 (9.2) 16 (18.6)
Antipsychotics 7 (8.1) 9 (10.5)
Antiepileptics 4 (4.6) 6 (7.0)
Acetaminophen 49 (56.3) 71 (82.6)
Notes: Missing values were <1.5% for immigrant status, employment, unplanned 
pregnancy, smoking, fertility problems, folate use, and alcohol use and between 
2.5% and 3.0% for neuroticism traits. aIndicates use of folate before and/or during 
pregnancy; bwomen having the first language different from the official main language 
in the country of residence; cindicates alcohol consumption after awareness of 
the pregnancy; dmeasured via the Big Five Inventory personality scale; edefined as 
self-reported asthma, allergy, hypothyroidism, epilepsy, diabetes (type I or II), and 
rheumatic or cardiovascular diseases.
Abbreviation: SD, standard deviation.
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Discussion
This study is the first to report self-reported antenatal and 
postnatal depressive symptoms in women across 12 European 
countries using uniform data collection and provides novel 
insights into the association of antidepressant treatment in 
pregnancy with postnatal symptom severity. On the basis of 
the EPDS, we found a substantial disparity in the prevalence 
of depressive symptoms across the countries. The period 
prevalence for moderate-to-very severe depressive symp-
toms, albeit with some amount of uncertainty, was higher 
in the western and eastern regions relative to the northern 
region, both in the antenatal period (6.8%–7.5% vs 4.3%) 
and postnatal period (7.6% vs 4.7%). These estimates are 
broadly in the range of those of major depression identified 
in some of the prior research (3%–5% during pregnancy, 
up to 6% during the first year postpartum).3,4,7,29 However, 
higher rates (15%–25%) have been identified in women 
from low- to middle-income countries,9,30,31 which supports 
our findings in relation to some of the investigated popula-
tions. We noted an inverse relationship between reporting a 
psychiatric disorder during pregnancy and symptom severity 
indicated by the EPDS score, particularly among women in 
Eastern Europe. This scenario could certainly reflect a lack 
of awareness of perinatal mental illnesses and inappropriate 
treatment and a still existing stigmatization of people with 
psychiatric diseases in this region.32 Given the deleterious 
effect of perinatal depression on the mother, child, and 
 family as a whole,33,34 our findings deserve attention and 
point to a crucial need of resource allocation for screening 
and treatment of perinatal mental disorders across Europe 
and particularly in the eastern region.
Our prevalence estimates of mild depressive symptoms 
were somewhat higher than those found by some5,35 although 
not all prior studies.36,37 Difference in study design, popula-
tions, or EPDS cutoff scores may not account entirely for the 
disparate findings.19,20,36 We adopted survey weight adjust-
ment, which enabled our estimates to be representative for 
high-risk women (ie, with younger age and lower education), 
often underrepresented in prior studies.31,37 The use of a single 
EPDS measurement,38 or a more honest disclosure of depres-
sive symptoms in a web-based, anonymous questionnaire 
versus face-to-face interview, may also have contributed. 
It is difficult to assess whether the varying sociocultural 
context, the validation status of the EPDS in the different 
languages, selection of more educated and primiparous 
women, or the Internet-administered EPDS may have affected 
our results.8,18,39,40
A key finding of this study was that treatment with anti-
depressants during pregnancy, mainly SSRIs, may have a 
preventive, medium size effect on postnatal depressive symp-
toms. This aligns with some albeit not all prior studies on the 
detrimental effect of antidepressant discontinuation in preg-
nancy on maternal perinatal mental health.12–15 Our associa-
tion was only evident in the early postpartum, ie, the 6-month 
Table 4 Association between antidepressant use during pregnancy and postnatal depressive symptoms severity as measured by the 
main and subdimensions of the EPDS (n=173)
Antidepressant use Any postnatal time, <1 year since birth Stratification by time since birth
Crude modela Weighted modela,b Weighted modela,b
b 95% CI b 95% CI b 95% CI b 95% CI
Any time, <1 year (n=173) <25 weeks (n=65) ≥25 weeks (n=108)
EPDS, total score
At any time 
−0.38 −0.71, −0.05** −0.34 −0.66, −0.02** −0.74 −1.24, −0.24** −0.03 −0.44, 0.39
Two or three trimesters
−0.45 −0.79, −0.11** −0.38 −0.72, −0.04** −0.86 −1.41, −0.32** 0.04 −0.42, 0.50
EPDS, subdimensions
Nonspecific depressive symptoms
At any time
−0.25 −0.59, 0.07 −0.30 −0.62, 0.03 −0.54 −1.03, −0.04** −0.11 −0.55, 0.33
Two or three trimesters 
−0.30 −0.64, 0.03 −0.31 −0.65, 0.04 −0.66 −1.19, −0.13** 0.01 −0.45, 0.47
Anxiety symptoms
At any time
−0.53 −0.89, −0.17** −0.33 −0.70, 0.04 −0.75 −1.34, −0.16** −0.01 −0.45, 0.43
Two or three trimesters
−0.64 −1.02, −0.26* −0.44 −0.84, −0.03** −0.84 −1.52, −0.15** −0.07 −0.55, 0.41
Anhedonia
At any time
−0.21 −0.56, 0.15 −0.31 −0.68, 0.06 −0.84 −1.43, −0.25** 0.10 −0.35, 0.56
Two or three trimesters
−0.25 −0.60, 0.10 −0.34 −0.74, 0.05 −0.94 −1.53, −0.36** 0.18 −0.32, 0.67
Notes: Lower z scores indicate lower symptom severity, and higher scores indicate the converse. *p≤0.001, **0.001<p<0.05. aWomen not medicated with antidepressants in 
pregnancy constituted the reference group for all the analyses (n=87); bmodels weighted with inverse probability of treatment weighting using the propensity score, estimated 
using maternal covariates and survey weight. 
Abbreviations: CI, confidence interval; EPDS, Edinburgh Postnatal Depression Scale.
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period since childbirth, and of slightly greater magnitude on 
the anxiety and anhedonia symptom subdimensions. Putnam 
et al21 found these two symptom subdimensions to be promi-
nent with early postpartum onset and of notable severity. 
The elevated pharmacotherapy rate and the high average 
EPDS score in the psychiatric sample are indeed suggestive 
of severe mental illness.41 Antidepressants have been shown 
to have greater benefit in severely ill nonpregnant patients,42 
and this may also be true in the perinatal context, although 
the interplay between the perinatal hormonal changes and the 
pharmacological action of antidepressants remains elusive. 
Nevertheless, these maternal correlates may also plausibly 
reflect a suboptimal treatment of the psychiatric disorder and/
or an inadequate dosing of antidepressants. Pregnancy is a 
major determinant of discontinuation of a needed pharma-
cotherapy, and the drug doses prescribed during this period 
are often lower than those effective.41 Thus, if this holds true, 
the benefit of an optimal treatment with antidepressants in 
terms of adherence and dosage could be larger than that 
found in this study. 
Bias due to the selection of mothers with more favor-
able mental health in the early postpartum, and unmeasured 
factors such as antidepressant treatment in the postnatal 
period, could possibly explain our findings. Nevertheless, 
if our observed associations were completely attributable to 
postnatal antidepressant use, we would have expected similar 
point estimates for the early and late postnatal period. Our 
observed associations have to be corroborated or refuted 
by longitudinal studies, but at present they provide some 
insights into the importance of exploring perinatal mental 
health from a (multi)dimensional perspective. Antidepressant 
treatment during pregnancy, in particular with SSRIs, poses 
critical challenges to pregnant women and their clinicians 
given the contradictory findings across multiple studies and 
the diverged debate on their short-term and long-term repro-
ductive safety.11,43 However, suboptimally treated antenatal 
depression and anxiety may pose comparable fetal risks,34,44 
and they are important risk factors for maternal mental health 
postpartum.45 An individual-based assessment of both the 
maternal psychiatric disorder and the benefit–risk ratio of 
antidepressant pharmacotherapy during pregnancy is essen-
tial to prevent harmful effects on both mother and child.
Strengths and limitations
A major strength is the use of a self-reported scale with good 
reliability designed to measure perinatal mood specifically, 
validated against clinical interview.18,19 By doing so, we could 
also explore depressive symptoms from a dimensional per-
spective and on a subdomain level. Data collection was con-
ducted uniformly in all participating countries via utilization 
of an anonymous electronic questionnaire, which enabled us 
to potentially reach a large proportion of the birthing popula-
tion. This approach allowed us to measure perinatal depres-
sion also in low-to middle-income countries and facilitated 
women’s disclosure of depressive symptoms. We corrected 
our prevalence estimates and association measures by survey 
weight adjustment, allowing the findings to be representative 
of the target population in terms of age and education. The 
IPTW approach set the difference in baseline characteristics 
between medicated and nonmedicated women to minimum. 
One important limitation is the lack of the temporal 
component. Treatment with antidepressants was reported 
retrospectively by mothers, which make their associations 
with postnatal symptom response valid. The psychiatric 
disorders were self-reported by the participants and not 
based on medically confirmed diagnoses, and their time of 
onset was not captured. However, the psychiatric sample 
correlates are suggestive of high psychiatric morbidity, and 
women were specifically asked to indicate whether they had 
chronic depression or anxiety. We did not have information 
about the history of psychiatric disorders and prior treat-
ments, past or ongoing nonpharmacological psychotherapy, 
and use of antidepressant before or after pregnancy. We 
measured depressive symptoms only once, which could have 
overestimated our prevalence estimates.19 Information about 
medication use during pregnancy depended on the accuracy 
of the woman’s reporting. The small sample size limited 
the statistical power of country-specific analyses and of the 
postnatal strata by the time since childbirth. The question-
naire was only available through Internet websites, which 
did not permit calculation of a conventional response rate, 
and a selection bias of the target population cannot be ruled 
out. However, recent epidemiological studies indicate rea-
sonable validity of web-based recruitment methods,46,47 and 
the overall Internet penetration rate is relatively high among 
women of childbearing age.48 We have previously assessed 
the study’s external validity on an individual country and 
found that, on average, the women in the study had higher 
education and were slightly more often primiparous than 
the general birthing populations in various countries.17 It is 
possible that selection bias may have affected our association 
measures and potentially underestimated and overestimated 
the antidepressant effects on the anhedonia and nonspecific 
depressive symptom subdimensions, respectively.
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Conclusion
In this study, we found a differential prevalence of depres-
sive symptoms across the countries in both the antenatal 
and postnatal periods. Women with more severe depressive 
symptoms based on the EPDS score less often reported 
to suffer from a psychiatric disorder during pregnancy. 
Taken together, this raises concern about unrecognition 
and suboptimal treatment of perinatal mental illnesses, 
particularly in some specific countries. Although longitu-
dinal studies are needed to confirm or refute this associa-
tion, women treated with antidepressant during pregnancy 
were less likely to report postnatal depressive symptoms, 
particularly in the early postpartum period, compared 
with the nonmedicated counterpart. Women should be 
empowered to develop an evidence-based understanding, 
not only solely of the potential risks but also of the ben-
efits of antidepressant treatment in pregnancy in order to 
optimize maternal–child health.
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Supplementary materials
Methods
Additional details on “Antenatal and postnatal 
depressive symptoms”
Information about the use of validated and/or translated ver-
sions of the original Edinburgh Postnatal Depression Scale 
(EPDS) in the current study has been provided elsewhere.1 
The EPDS developers were acknowledged in each electronic 
questionnaire under the section presenting the scale. Imputed 
values were generated when respondents completed at least 
eight of the 10 items on the EPDS, using the estimation–
maximization algorithm.2 Values were imputed for 3.3% of 
the women. 
Additional details on “Data analysis”
The statistical office of the European Union provided 
information about the distribution of these variables among 
women of childbearing age in each participating country, 
except Russia.3 For the latter, we used average data for 
the other eastern European countries.3,4 Each woman was 
assigned a weight, obtained by dividing the population 
proportion by the corresponding sample proportion in 
each age-by-education strata.4 Women underrepresented 
in our sample were assigned a weight >1, while those 
overrepresented received a weight <1. The survey weight 
for the entire study sample had a mean of 0.98 (range 
=0.13–33.05).
The propensity score was estimated using the survey 
weight and the following maternal covariates: region of 
residency, age (squared term), education, immigrant status, 
parity, marital status, unplanned pregnancy, smoking and 
alcohol use during pregnancy, neurotic traits, comedication 
in pregnancy with anxiolytics and sedatives, and antipsychot-
ics. These covariates were selected on the basis of subject 
knowledge, prior research, and characteristics of the resulting 
propensity score. 
Power analysis
The study was adequately powered to detect fairly medium 
differences in postnatal depressive symptoms. With power 
analysis for unpaired samples of the difference between two 
independent means (α=0.05), we had 80% power to detect 
effect sizes of 0.45.
Sensitivity analyses
Various sensitivity analyses were conducted to assess the 
robustness of the findings. We excluded women who com-
pleted the EPDS within the first 4 weeks postpartum to limit 
the risk of measuring “baby blues” from the descriptive 
analysis. The inverse probability of treatment weighting 
(IPTW) analysis is very sensitive to extreme weights; thus, 
we progressively truncated the IPTW at 1st/99th and 5th/95th 
percentile.5 The weighted analyses were also restricted 
to women on antidepressant monotherapy or solely with 
depression and/or anxiety. To account for country variation, 
we replicated the generalized linear models of the primary 
analyses with the inclusion of a random effect for country of 
residence, plus weighting by the composite weight.
Results
Additional details on “Results”
The total EPDS and the three subdimensions had good 
reliability in both the samples (Cronbach’s α =0.80–0.86), 
also when restricted to women with a psychiatric disorder 
(0.88–0.89). 
The generated IPTW had a mean of 1.04 for both the 
antidepressant “exposure” groups, with ranges of 0.54–8.17 
(any time during pregnancy) and 0.53–11.78 (two or three 
trimesters).
Sensitivity and stratified analysis
Exclusion of women in the earliest postnatal period (0–4 
weeks since childbirth, n=253) did not meaningfully affect 
the overall and region-specific postnatal mean EPDS scores 
(1% mean difference).
Exclusion of women on polytherapy (n=4) or with disor-
ders other than depression or anxiety (n=6), or the progressive 
IPTW truncation, yielded an effect estimate similar to those 
of the main analysis.
The results of the sensitivity analysis accounting for the 
random effect by the country of residence did not materially 
differ from those of the main analysis. The point estimate 
for antidepressant treatment during pregnancy and overall 
depressive symptom severity (total EPDS) changed by 3% 
(adjusted β =−0.33, 95% CI =−0.59, −0.08). In all the EPDS 
subdimensions, the CI of the association measures did not 
cross the null effect. 
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Figure S1 Antenatal EPDS weighted mean score and 95% CI, overall and by self-reported psychiatric disorder (n=4308).
Notes: No EPDS estimate is presented for women with psychiatric disorders in Croatia and Slovenia due to small sample size. Mean values and corresponding 95% CI were 
survey weight adjusted. The survey weight accounted for educational level within age strata for each individual country among women of childbearing age. Population data for 
2012 from European Commission, Eurostat. Population by educational attainment level, sex and age (%) - main indicators; 2017 [updated February 28, 2018; cited November 
8, 2017]. Available from: http://ec.europa.eu/eurostat/web/products-datasets/-/edat_lfse_03. Accessed August 17, 2017.3
Abbreviations: CI, confidence interval; EPDS, Edinburgh Postnatal Depression Scale.
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Figure S2 Postnatal EPDS weighted mean score and 95% CI, overall and by self-reported psychiatric disorder (n=3761).
Notes: No EPDS estimate is presented for women with psychiatric disorders in Croatia due to low numbers. No estimate is presented for women with psychiatric disorders 
in Slovenia because of small sample size. Mean values and corresponding 95% CI were survey-weight-adjusted. The survey weight accounted for educational level within age 
strata for each individual country among women of childbearing age. Population data for 2012 from European Commission, Eurostat. Population by educational attainment 
level, sex and age (%) - main indicators; 2017 [updated February 28, 2018; cited November 8, 2017]. Available from: http://ec.europa.eu/eurostat/web/products-datasets/-/
edat_lfse_03. Accessed August 17, 2017.3
Abbreviations: CI, confidence interval; EPDS, Edinburgh Postnatal Depression Scale.
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Figure S3 Balance of covariates (standardized difference) after the application of the IPTW for antidepressant use at any time during pregnancy.
Abbreviation: IPTW, inverse probability of treatment weight.
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Figure S4 Balance of covariates (standardized difference) after the application of the IPTW for antidepressant use in two or three trimesters.
Abbreviation: IPTW, inverse probability of treatment weight.
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